Peo in Int of AFH

Colorado Court of Appeals·Decided June 11, 2026·No. 26CA0553·Unpublished

Opinion

26CA0553 Peo in Interest of AFH 06-11-2026

COLORADO COURT OF APPEALS

Court of Appeals No. 26CA0553 Pueblo County District Court No. 26MH30032 Honorable Gregory J. Styduhar, Judge

The People of the State of Colorado,

Petitioner-Appellee,

In the Interest of A.F.H.,

Respondent-Appellant.

ORDER AFFIRMED

Division III Opinion by JUDGE KUHN Freyre and Johnson, JJ., concur

NOT PUBLISHED PURSUANT TO C.A.R. 35(e) Announced June 11, 2026

Cynthia Mitchell, County Attorney, Kate H. Shafer, Special Assistant County Attorney, Pueblo, Colorado, for Petitioner-Appellee

Tezak Law, P.C., Mary Tezak, Florence, Colorado, for Respondent-Appellant ¶1 A.F.H. appeals the district court’s order authorizing staff at the

Colorado Mental Health Hospital in Pueblo (CMHHIP) to medicate

him against his will. We affirm.

I. Background

¶2 A.F.H. was admitted to CMHHIP after being found incompetent

to proceed on criminal charges. According to the affidavit and

testimony of Dr. Hareesh Pillai, the psychiatrist who supervises

A.F.H.’s care and treatment, A.F.H. suffers from an unspecified

mood disorder that causes disorganized thinking and behavior,

agitation, delusions, and paranoia. He has a long history of

psychiatric hospitalizations, mental health holds, and

incarcerations.

¶3 A.F.H. was prescribed Risperdal and Depakote in jail, but he

had not been compliant with those prescriptions before his arrival

at CMHHIP. About three weeks after A.F.H. arrived at CMHHIP,

staff began administering Zyprexa and Depakote on an emergency

basis to manage his episodes of aggression, including slamming

and breaking a door, yelling and screaming curses, and glaring and

posturing toward staff with his fists clenched. After a few days on

1 those medications, A.F.H. displayed notable improvement in his

symptoms.

¶4 The People petitioned for a six-month order authorizing the

involuntary administration of Zyprexa, Depakote, and Haldol, along

with laboratory work and testing to monitor possible side effects.

The district court held an evidentiary hearing, where Dr. Pillai

clarified that CMHHIP staff would continue scheduled doses of

Zyprexa and Depakote, and they would administer Haldol as a

backup medication only if A.F.H. refused oral doses of Depakote.

Dr. Pillai further testified about each of the four elements required

for the involuntary administration of medication under People v.

Medina, 705 P.2d 961, 973 (Colo. 1985).1 As to A.F.H.’s interest in

refusal, Dr. Pillai testified that he knew of no bona fide and

legitimate reason for A.F.H. to refuse Zyprexa and Depakote —

1 When the State seeks to administer antipsychotic drugs to a

mentally ill criminal defendant involuntarily so that he can stand trial, a reviewing court applies the Supreme Court’s test in Sell v. United States, 539 U.S. 166, 178 (2003). However, reviewing courts apply state law tests if the State, as here, seeks to administer antipsychotics involuntarily for a different purpose, including a purpose “related to the individual’s dangerousness, or . . . the individual’s own interests where refusal to take drugs puts his health gravely at risk.” Id. at 181-82.

2 A.F.H.’s symptoms had been increasing in severity when off the

medication but had markedly improved since taking Zyprexa and

Depakote, and he had reported no significant side effects other than

some sedation.

¶5 A.F.H. also testified. He explained that he objected to taking

the prescribed medications because did not have a mental illness

and he preferred to treat his illnesses, including scoliosis, with a

vegan diet. He alleged that he suffered from several side effects

from Zyprexa or Depakote, including (1) lethargy and slow

movement; (2) restlessness; (3) muscle pain and neck symptoms,

which he also attributed to scoliosis and soreness from an injection;

and (4) issues with throat swelling, speaking, and swallowing,

though he emphasized that those symptoms were mild or

nonexistent as compared to when he was taking Abilify.

¶6 At the conclusion of the hearing, the district court found Dr.

Pillai’s testimony to be credible and persuasive. It found A.F.H.’s

testimony, particularly as to his alleged side effects, not reliable.

The court ultimately found that the People had provided clear and

convincing evidence for each of the Medina elements, and the court

3 issued an order authorizing CMHHIP staff to administer all the

requested medications for a period of six months.

¶7 On appeal, A.F.H. challenges the sufficiency of the evidence

supporting the court’s order.

II. Analysis

¶8 A.F.H. challenges the sufficiency of the evidence for only the

fourth Medina element. He argues that he “has a bona fide and

legitimate interest in refusing medication due to both the risk of

potential side effects and the adverse effects he is currently

experiencing” and “his decision to refuse medication should be

understood as a considered response to legitimate health risks

rather than noncompliance.” Accordingly, we review whether the

evidence in the record is sufficient to support the court’s decision

on the fourth Medina element.2

A. Applicable Law and Standard of Review

¶9 A district court may authorize the involuntary administration

of medication to a patient only if the People establish each of the

2 We decline to address A.F.H.’s challenge, made for the first time in

his reply brief on appeal, to the medication dosages that the district court approved. See In Interest of L.B., 2017 COA 5, ¶ 48 (“We do not consider arguments raised for the first time in a reply brief.”).

4 following elements by clear and convincing evidence: (1) the patient

is incompetent to participate effectively in the treatment decision;

(2) treatment by medication is necessary either to prevent a

significant and likely long-term deterioration in the patient’s mental

condition or to prevent the likelihood of the patient causing serious

harm to themself or others in the institution; (3) a less intrusive

treatment alternative isn’t available; and (4) the patient’s need for

treatment with medication is sufficiently compelling to override

their bona fide and legitimate interest in refusing medication.

Medina, 705 P.2d at 973; see People in Interest of Strodtman, 293

P.3d 123, 131 (Colo. App. 2011). A treatment provider’s testimony

alone may constitute clear and convincing evidence. See People v.

Pflugbeil, 834 P.2d 843, 846-47 (Colo. App. 1992).

¶ 10 When, as here, a patient challenges the sufficiency of the

evidence, we review the record as a whole and, viewing it in the light

most favorable to the People, determine whether the evidence is

sufficient to support the court’s decision. People in Interest of

Ramsey, 2023 COA 95, ¶ 23. We review the court’s conclusions of

law de novo and defer to its findings of fact if supported by evidence

in the record. People v. Marquardt, 2016 CO 4, ¶ 8. We also defer

5 to the district court’s resolution of evidentiary conflicts and its

Free access — add to your briefcase to read the full text and ask questions with AI

Peo in Int of AFH, (Colo. Ct. App. 2026).

Peo in Int of AFH (Peo in Int of AFH) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Sell v. United States
539 U.S. 166 (Supreme Court, 2003)
People v. Medina
705 P.2d 961 (Supreme Court of Colorado, 1985)
People v. Pflugbeil
834 P.2d 843 (Colorado Court of Appeals, 1992)
People v. Marquardt
2016 CO 4 (Supreme Court of Colorado, 2016)
People ex rel. Strodtman
293 P.3d 123 (Colorado Court of Appeals, 2011)